Last reviewed · How we verify
Amlitelimab DP2
At a glance
| Generic name | Amlitelimab DP2 |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlitelimab DP2 CI brief — competitive landscape report
- Amlitelimab DP2 updates RSS · CI watch RSS
- Sanofi portfolio CI